Observational Study of Hypoxia in Melanoma

This study is looking at how oxygen levels (hypoxia) in melanoma tumors might be linked to how the disease progresses. Researchers want to see if higher hypoxia, measured using a drug called pimonidazole, is connected to worse progression-free survival (PFS), which means the time a person lives without their cancer getting worse. You might be able to join if you have melanoma that requires a sentinel lymph node biopsy (SLNB), which is a procedure to check if cancer has spread to nearby lymph nodes. The study aims to enroll about 50 people. The current status of recruitment is unclear.

Study design
This is an observational study, meaning researchers will observe participants without assigning specific treatments. It aims to enroll 50 participants.
What's involved
Participants will take pimonidazole by mouth before their scheduled biopsy. This drug is not for treatment but helps measure oxygen levels in the tumor.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years from the date of their surgery to track progression-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06831071

Evaluation of Hypoxia in Primary Melanoma

Recruiting
Not specifiedAges 18+Observational
Yana Najjar
~50 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Pimonidazole

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor Hypoxia
Measured over Day of surgery
+2 more outcomes measured
Melanoma
1 sites across 1 states
Pennsylvania1
  • Yana M Najjar, MD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

  • Tumor HypoxiaDay of surgery

    Hypoxia (decreased oxygen levels) in the primary tumor in patients with primary melanoma as measured by hypoxyprobe staining in primary tumor through CODEX imaging.

  • Progression Free SurvivalUp to 5 years (from date of surgery)

    Median number of months from time of surgery to regression, progression or death, whichever occurs first. Progression is defined as observable disease upon visual evaluation of surgical (anatomical) site.

  • Sentinel Lymph Node HypoxiaDay of surgery

    Hypoxia (decreased oxygen levels) in the sentinel lymph node (SLN) in patients with primary melanoma as measured by hypoxyprobe staining in primary tumor through CODEX imaging.